Edison Issues Report on Record
LONDON, November 8, 2013 /PRNewswire/ --
Edison Investment Research, a leading international investment research firm, releases an update on Record (LSE: REC), an investment company listed on the London Stock Exchange. In October, Edison initiated full coverage on the company.
In the report, Growing pipeline of potential US mandates, Edison analyst Jonathon Goslin highlights how Record is reducing the average fees it will charge to both new and existing dynamic hedging clients, in a bid to compete effectively for new business in the large US market and maintain its policy of charging similar fees for similar mandates.
For the full report see: http://www.edisoninvestmentresearch.com/research/company/record
All reports Edison publishes are available to download free of charge from its website http://www.edisongroup.com.
About Edison Investment Research
Edison, the investment intelligence firm, is the future of investor interaction with corporates. The team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. It provides services to more than 400 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Record is a specialist currency manager, providing currency hedging and return-seeking mandates to institutional clients. Services include passive and dynamic hedging and return-seeking currency strategies via funds or segregated accounts.
For more information please contact:
Jonathon Goslin, Edison Investment Research, +44(0)20-3077-5765
SOURCE Edison Investment Research
More by this Source
Edison Investment Research initiates coverage on Cytori Therapeutics
Feb 04, 2014, 10:32 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.